WO2007075751A1 - Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression - Google Patents
Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression Download PDFInfo
- Publication number
- WO2007075751A1 WO2007075751A1 PCT/US2006/048538 US2006048538W WO2007075751A1 WO 2007075751 A1 WO2007075751 A1 WO 2007075751A1 US 2006048538 W US2006048538 W US 2006048538W WO 2007075751 A1 WO2007075751 A1 WO 2007075751A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- depression
- group
- benzo
- dihydro
- compound
- Prior art date
Links
- 0 CC(C1C(*C(CC2)Oc3c2cccc3)C1)OCCC*NC Chemical compound CC(C1C(*C(CC2)Oc3c2cccc3)C1)OCCC*NC 0.000 description 1
- XBXLSFXEVLOKGB-JVVDXDAESA-N C[C@@H]1Oc2cc(C/C=C3/SC3)ccc2O1 Chemical compound C[C@@H]1Oc2cc(C/C=C3/SC3)ccc2O1 XBXLSFXEVLOKGB-JVVDXDAESA-N 0.000 description 1
- YXPDUQAPPACYDU-UHFFFAOYSA-N NS(NCC1COc2ccccc2OC1)(=O)=O Chemical compound NS(NCC1COc2ccccc2OC1)(=O)=O YXPDUQAPPACYDU-UHFFFAOYSA-N 0.000 description 1
- KAZJLTGACHBMSU-UHFFFAOYSA-N NS(NCC1Oc2ccccc2O1)(=O)=O Chemical compound NS(NCC1Oc2ccccc2O1)(=O)=O KAZJLTGACHBMSU-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Definitions
- the present invention is directed to the use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression, including both monotherapy and co-therapy with at least one anti-depressant.
- Unipolar depression is defined as depressed mood on a daily basis for a minimum duration of two weeks.
- An episode may be characterized by sadness, indifference or apathy, or irritability and is usually associated with a change in a number of neurovegetative functions, including sleep patterns, appetite and body weight, motor agitation or retardation, fatigue, impairment in concentration and decision making, feelings of shame or guilt, and thoughts of death or dying (Harrison's Principles of Internal Medicine, 2000).
- the criteria for a major depressive episode includes five or more symptoms present during the same 2-week period, where this represents a change from previous functioning; and where at least one of the symptoms is either depressed mood or loss of interest or pleasure.
- Symptoms of a depressive episode include depressed mood; markedly diminished interest or pleasure in all, or almost all, activities most of the day; weight loss when not dieting or weight gain, or decrease or increase in appetite nearly every day; insomnia or hypersomnia nearly every day; psychomotor agitation or retardation nearly every day; fatigue or loss of energy nearly every day; feelings of worthlessness or excessive or inappropriate guilt nearly every day; diminished ability to think or concentrate, or indecisiveness, nearly every day; recurrent thoughts of death, recurrent suicidal ideation without a specific plan, or a suicide attempt or a specific plan for committing suicide. Further, the symptoms cause clinically significant distress or impairment in social, occupational, or other important areas of functioning. (Diagnostic and Statistical Manual of Mental Disorders, 4 th Edition, Text Revision, American Psychiatric Association, 2000)
- Current treatment options for unipolar depression include monotherapy or combination therapy with various classes of drugs including mono-amine oxidase inhibitors, tricyclics, serotonin reuptake inhibitors, serotonin noradrenergic reuptake inhibitors, noradrenergic and specific serotonergic agents, noradrenaline reuptake inhibitor, "natural products” (such as Kava- Kava, St. John's Wort), dietary supplement (such as s-adenosylmethionine) and others.
- drugs including mono-amine oxidase inhibitors, tricyclics, serotonin reuptake inhibitors, serotonin noradrenergic reuptake inhibitors, noradrenergic and specific serotonergic agents, noradrenaline reuptake inhibitor, "natural products” (such as Kava- Kava, St. John's Wort), dietary supplement (such as s-adenosylmethionine) and others.
- drugs used in the treatment of depression include, but are not limited to imipramine, amitriptyline, desipramine, nortriptyline, doxepin, protriptyline, trimipramine, maprotiline, amoxapine, trazodone, bupropion, chlomipramine, fluoxetine, citalopram, sertraline, paroxetine, fluvoxamine, nefazadone, venlafaxine, reboxetine, mirtazapine, phenelzine, tranylcypromine, and / or moclobemide (eg, J. M. KENT, Lancet 2000, 355, 911 -918; J.W. WILLIAMS JR, CD.
- moclobemide eg, J. M. KENT, Lancet 2000, 355, 911 -918; J.W. WILLIAMS JR, CD.
- treatment of resistant depression includes augmentation strategies including treatment with pharmacological agents such as, lithium, carbamazepine, and triiodothyronine, and the like (M. HATZINGER and E. HOLSBOER-TRACHSLER, Wien. Med. Wienschr. 1999, 149, 511-514; CB. NEMEROFF, Depress. Anxiety 1996- 1997, 4, 169-181 ; T.A. KETTER, R.M. POST, P.I. PAREKH and K. WORTHINGTON, J. Clin. Psychiatry 1995, 56, 471 -475; RT. JOFFE, W. SINGER, A.J. LEVITT, C. MACDONALD 1 Arch. Gen. Psychiatry 1993, 50, 397- 393).
- pharmacological agents such as, lithium, carbamazepine, and triiodothyronine, and the like
- Dysthymia is defined as a mood disorder characterized by chronic depressed mood for a period of at least 2 years. Dysthymia can have a persistent or intermittent course and the depressed mood occurs for most of the day, for more days than not, and for at least 2 years. ⁇ Diagnostic and Statistical Manual of Mental Disorders, 4 th Edition, American Psychiatric Association, 1994).
- Bipolar disorder is characterized by unpredictable swings in mood between mania and depression (bipolar I disorder) or between hypomania and depression (bipolar Il disorder) , ⁇ Diagnostic and Statistical Manual of Mental Disorders, 4 th Edition, American Psychiatric Association, 1994).
- Antidepressant use in bipolar disorder is generally, intentionally restricted to avoid the risk of mania and the risk of rapid cycling induced by antidepressants in bipolar disorder (HJ. MOLLER and H. GRUNZE, Eur. Arch. Psychiatry Clin. Neurosci. 2000, 250, 57-68; J. R. CALABRESE, DJ. RAPPORT, S.E. KIMMEL, and M. D. SHELTON, Eur.
- the present invention is directed to a method for the treatment of depression comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I)
- R 1 and R 2 are each independently selected from the group consisting of hydrogen and lower alkyl
- R 4 is selected from the group consisting of hydrogen and lower alkyl; a is an integer from 1 to 2;
- each R 5 is independently selected from the group consisting of halogen, lower alkyl and nitro;
- the present invention is further directed to a method for the treatment of depression comprising administering to a subject in need thereof a therapeutically effective amount of compound of formula (II)
- the present invention is further directed to a method for the treatment of depression comprising administering to a subject in need thereof co-therapy with a therapeutically effective amount of at least one antidepressant and a compound of formula (I) or formula (II) as herein defined.
- Exemplifying the invention is a method of treating major depressive disorder, unipolar depression, treatment refractory depression, resistant depression, anxious depression or dysthymia comprising administering to a subject in need thereof a therapeutically effective amount of any of the compounds or pharmaceutical compositions described above.
- the present invention is directed to a method of treating major depressive disorder, unipolar depression, treatment refractory depression, resistant depression, anxious depression or dysthymia comprising administering to a subject in need thereof at least one antidepressant in combination with any of the compounds or pharmaceutical compositions described above.
- the present invention is directed to a method for the treatment of depression comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I)
- the present invention is further directed to the treatment of depression comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I) or formula (U) in combination with at least one antidepressant.
- depression shall be defined to include major depressive disorder (including single episode and recurrent), unipolar depression, treatment-refractory depression, resistant depression, anxious depression and dysthymia (also referred to as dysthymic disorder). Further, the term “depression” shall encompass any major depressive disorder, dysthymic disorder, mood disorders due to medical conditions with depressive features, mood disorders due to medical conditions with major depressive like episodes, substance-induced mood disorders with depressive features and depressive disorder not otherwise specific as defined by their diagnostic criteria, as listed in the Diagnostic and Statistical Manual of Mental Disorders, 4 th Edition, Text Revision, American Psychiatric Association, 2000. Preferably, the depression is major depressive disorder, unipolar depression, treatment- refractory depression, resistant depression or anxious depression. More preferably, the depression is major depressive disorder.
- the term "antidepressant” shall mean any pharmaceutical agent which treats depression. Suitable examples include, but are not limited to mono-amine oxidase inhibitors such as phenelzine, tranylcypromine, moclobemide, and the like; tricyclics such as irnipramine, amitriptyline, desipramine, nortriptyline, doxepin, protriptyline, trimipramine, chlomipramine, amoxapine, and the like; tetracyclics such as maprotiline, and the like; non-cyclics such as nomifensine, and the like; triazolopyridines such as trazodone, and the like; serotonin reuptake inhibitors such as fluoxetine, sertraline, paroxetine, citalopram, fluvoxamine, and the like; serotonin receptor antagonists such as nefazadone, and the like;
- the antidepressant is selected from the group consisting of fluoxetine, imipramine, bupropion, venlafaxine and sertaline.
- subject refers to an animal, preferably a mammal, most preferably a human, who has been the object of treatment, observation or experiment.
- therapeutically effective amount means that amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinician, which includes alleviation of the symptoms of the disease or disorder being treated.
- the present invention is directed to co-therapy or combination therapy, comprising administration of one or more compound(s) of formula (I) or formula (II) and one or more antidepressants
- therapeutically effective amount shall mean that amount of the combination of agents taken together so that the combined effect elicits the desired biological or medicinal response.
- the therapeutically effective amount of co-therapy comprising administration of a compound of formula (I) or formula (II) and at least on antidepressant would be the amount of the compound of formula (I) or formula (II) and the amount of the antidepressant that when taken together or sequentially have a combined effect that is therapeutically effective.
- the amount of the compound of formula (I) or formula (II) and/or the amount of the antidepressant individually may or may not be therapeutically effective.
- the terms "co-therapy” and “combination therapy” shall, mean treatment of a subject in need thereof by administering one or more compounds of formula (I) or formula (II) in combination with one or more antidepressant(s), wherein the compound(s) of formula (I) or formula (II) and the antidepressant(s) are administered by any suitable means, simultaneously, sequentially, separately or in a single pharmaceutical formulation.
- the number of dosages administered per day for each compound may be the same or different.
- the compound(s) of formula (I) or formula (II) and the antidepressant(s) may be administered via the same or different routes of administration.
- suitable methods of administration include, but are not limited to, oral, intravenous (iv), intramuscular (im), subcutaneous (sc), transdermal, and rectal.
- Compounds may also be administered directly to the nervous system including, but not limited to, intracerebral, intraventricular, intracerebroventricular, intrathecal, intracistemal, intraspinal and / or peri-spinal routes of administration by delivery via intracranial or intravertebral needles and / or catheters with or without pump devices.
- the compound(s) of formula (I) or formula (II) and the antidepressant(s) may be administered according to simultaneous or alternating regimens, at the same or different times during the course of the therapy, concurrently in divided or single forms.
- a method for the treatment of depression comprising administering to a subject in need thereof a combination of one or more compounds of formula (I) or formula (II) with one or more compounds selected from the group consisting of mono-amine oxidase inhibitors such as phenelzine, tranylcypromine, moclobemide, and the like; tricyclics such as imipramine, amitriptyline, desipramine, nortriptyline, doxepin, protriptyline, trimipramine, chlomipramine, amoxapine, and the like; tetracyclics such as maprotiline, and the like; non-cyclics such as nomifensine, and the like; triazolopyridines such as trazodone, and the like; serotonin reuptake inhibitors such as fluoxetine, sertraline, paroxetine, citalopram, fluvoxamine, escitalopram o
- John's Wort, and the like dietary supplements such as s-adenosylmethionine, and the like; and neuropeptides such as thyrotropin-releasing hormone and the like, and the like; compounds targeting neuropeptide receptors such as neurokinin receptor antagonists and the like; and hormones such as triiodothyronine, and the like.
- In an embodiment of the present invention is a method for the treatment of depression comprising administering to a subject in need thereof a combination of .one or more compounds of formula (I) or formula (II) with one or more compounds selected from the group consisting of mono-amine oxidase inhibitors; tricyclics; tetracyclics; non-cyclics; triazolopyridines; serotonin reuptake inhibitors; serotonin receptor antagonists; serotonin noradrenergic reuptake inhibitors; serotonin noradrenergic reuptake inhibitors; noradrenergic and specific serotonergic agents; noradrenaline reuptake inhibitors; atypical antidepressants; natural products; dietary supplements; neuropeptides; compounds targeting neuropeptide receptors; and hormones.
- one or more compounds of formula (I) or formula (II) are administered in combination with one or more compounds selected from the group consisting of mono-amine oxidase inhibitors, tricyclics, serotonin reuptake inhibitors, serotonin noradrenergic reuptake inhibitors; noradrenergic and specific serotonergic agents and atypical antidepressants.
- one or more compounds of formula (I) or formula (II) are administered in combination with one or more compounds selected from the group consisting of mono-amino oxidase inhibitors, tricyclics and serotonin reuptake inhibitors.
- one or more compounds of formula (I) or formula (II) are administered in combination with one or more compounds selected from the group consisting of serotonin reuptake inhibitors.
- a method for the treatment of depression comprising administering to a subject in need thereof a combination of one or more compounds of formula (I) or formula (II) with one or more compounds selected from the group consisting of phenelzine, tranylcypromine, moclobemide, imipramine, amitriptyline, desipramine, nortriptyline, doxepin, protriptyline, trimipramine, chlomipramine, amoxapine, fluoxetine, sertraline, paroxetine, citalopram, fluvoxamine, venlafaxine, milnacipran, duloxetine, mirtazapine, bupropion, thyrotropin-releasing hormone and triiodothyronine.
- one or more compounds of formula (I) or formula (II) are administered in combination with one or more compounds selected from the group consisting of phenelzine, tranylcypromine, moclobemide, imipramine, amitriptyline, desipramine, nortriptyline, doxepin, protriptyline, trimipramine, chlomipramine, amoxapine, fluoxetine, sertraline, paroxetine, citalopram, fluvoxamine, venlafaxine, milnacipran, mirtazapine and bupropion.
- one or more compounds of formula (I) or formula (II) are administered in combination with one or more compounds selected from the group consisting of phenelzine, tranylcypromine, moclobemide, imipramine, amitriptyline, desipramine, nortriptyline, doxepin, protriptyline, trimipramine, chlomipramine, amoxapine
- one or more compounds of formula (I) or formula (II) are administered in combination with one or more compounds selected from the group consisting of phenelzine, tranylcypromine, moclobemide, imipramine, amitriptyline, desipramine, nortiptyline, doxepin, protriptyline, trimipramine, chlomipramine, amoxapine, fluoxetine, sertraline, paroxetine, citalopram, escitalopram and fluvoxamine.
- one or more compounds of formula (I) or formula (II) are administered in combination with one or more compounds selected from the group consisting of fluoxetine, sertraline, paroxetine, citalopram and fluvoxamine.
- a method for the treatment of depression comprising administering to a subject in need thereof a combination of one or more compounds of formula (I) or formula (II) with one or more compounds selected from the group consisting of neuropeptides such as thyrotropin-releasing hormone and the like; compounds targeting neuropeptide receptors such as neurokinin receptors antagonists and the like; and hormones such as triiodothyronine and the like.
- neuropeptides such as thyrotropin-releasing hormone and the like
- compounds targeting neuropeptide receptors such as neurokinin receptors antagonists and the like
- hormones such as triiodothyronine and the like.
- R 1 is selected from the group consisting of hydrogen and methyl.
- R 2 is selected from the group consisting of hydrogen and methyl.
- R 1 and R 2 are each hydrogen or R 1 and R 2 are each methyl.
- -(CH 2 ) a - is selected from the group consisting of -CH 2 - and -CH 2 -CH 2 -. In another embodiment of the present invention -(CH 2 ) a - is -CH 2 -.
- R 4 is selected from the group consisting of hydrogen and methyl, preferably, R 4 is hydrogen. In an embodiment of the present invention a is 1.
- b is an integer from 0 to 2.
- c is an integer from 0 to 2.
- b is an integer from 0 to 1.
- c is an integer from 0 to 1.
- the sum of b and c is an integer form 0 to 2, preferably an integer form 0 to 1.
- b is an integer from 0 to 2 and c is 0.
- benzo[1 ,4]dioxinyl In another embodiment of the present invention, is selected from the group consisting of 2-(2,3-dihydro-benzo[1 ,4]dioxinyl), 2-(7- methyl-2,3-dihydro-benzo[1 ,4]dioxinyl) and 2-(6-bromo-2,3-dihydro- benzo[1 ,4]dioxinyl).
- R 5 is selected from the group consisting of halogen and lower alkyl. In another embodiment of the present invention R 5 is selected from chloro, fluoro, bromo and methyl.
- the stereo-center on the compound of formula (I) is in the S-configu ration. In another embodiment of the present invention, the stereo-center on the compound of formula (I) is in the R-configuration.
- the compound of formula (I) is present as an enantiomerically enriched mixture, wherein the % enantiomeric enrichment (% ee) is greater than about 75%, preferably greater than about 90%, more preferably greater than about 95%, most preferably greater than about 98%.
- Additional embodiments of the present invention include those wherein the substituents selected for one or more of the variables defined herein (i.e. R 1 , R 2 , R 3 , R 4 , X-Y and A) are independently selected to be any individual substituent or any subset of substituents selected from the complete list as defined herein.
- Tables 1 and 2 below the column headed "stereo" defines the stereo-configuration at the carbon atom of the heterocycle attached at the starred bond. Where no designation is listed, the compound was prepared as a mixture of stereo-configurations. Where an "R” or “S” designation is listed, the stereo-configuration was based on the enantiomerically enriched starting material.
- halogen shall mean chlorine, bromine, fluorine and iodine.
- alkyl whether used alone or as part of a substituent group, includes straight and branched chains.
- alkyl radicals include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, t-butyl, pentyl and the like.
- lower when used with alkyl means a carbon chain composition of 1-4 carbon atoms.
- alkoxy shall denote an oxygen ether radical of the above described straight or branched chain alkyl groups. For example, methoxy, ethoxy, n-propoxy, sec-butoxy, t-butoxy, n-hexyloxy and the like.
- substituents e.g., alkyl, aryl, etc.
- that group may have one or more substituents, preferably from one to five substituents, more preferably from one to three substituents, most preferably from one to two substituents, independently selected from the list of substituents.
- phenyl-alkyl- amino-carbonyl-alkyl refers to a group of the formula
- crystalline forms for the compounds may exist as polymorphs and as such are intended to be included in the present invention.
- some of the compounds may form solvates with water (i.e., hydrates) or common organic solvents, and such solvates are also intended to be encompassed within the scope of this invention.
- the salts of the compounds of this invention refer to non-toxic "pharmaceutically acceptable salts.”
- Other salts may, however, be useful in the preparation of compounds according to .this invention or of their pharmaceutically acceptable salts.
- Suitable pharmaceutically acceptable salts of the compounds include acid addition salts which may, for example, be formed by mixing a solution of the compound with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulfuric acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid.
- suitable pharmaceutically acceptable salts thereof may include alkali metal salts, e.g., sodium or potassium salts; alkaline earth metal salts, e.g., calcium or magnesium salts; and salts formed with suitable organic ligands, e.g., quaternary ammonium salts.
- alkali metal salts e.g., sodium or potassium salts
- alkaline earth metal salts e.g., calcium or magnesium salts
- suitable organic ligands e.g., quaternary ammonium salts.
- representative pharmaceutically acceptable salts include the following: acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, calcium edetate, camsylate, carbonate, chloride, clavulanate, citrate, dihydrochloride, edetate, edisylate, estolate, esylate, fumarate, gluceptate, gluconate, glutamate, glycollylarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, .
- acids and bases which may be used in the preparation of pharmaceutically acceptable salts include the following: acids including acetic acid, 2,2-dichloroactic acid, acylated amino acids, adipic acid, alginic acid, ascorbic acid, L-aspartic acid, benzenesulfonic acid, benzoic acid, 4-acetamidobenzoic acid, (+)-camphoric acid, camphorsulfonic acid, (+)-(1S)-camphor-10-sulfonic acid, capric acid, caproic acid, caprylic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1 ,2- disulfonic acid, ethanesulfonic acid, 2-hydrocy-ethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, D-gluconic acid, D-glucoronic acid,
- a suitably substituted compound of formula (X), a known compound or compound prepared by known methods, is reacted with sulfamide, a known compound, preferably wherein the sulfamide is present in an amount in the range of about 2 to about 5 equivalents, in an organic solvent such as THF, dioxane, and the like, preferably at an elevated temperature in the range of about 50 0 C to about 100 0 C, more preferably at about reflux temperature, to yield the corresponding compound of formula (Ia).
- a suitably substituted compound of formula (X), a known compound or compound prepared by known methods is reacted with a suitably substituted compound of formula (Xl), a known compound or compound prepared by known methods, in the presence of a base such as TEA, DIPEA, pyridine, and the like, in an organic solvent such as DMF, DMSO, and the like, to yield the corresponding compound of formula (I).
- a base such as TEA, DIPEA, pyridine, and the like
- organic solvent such as DMF, DMSO, and the like
- a suitably substituted compound of formula (XII) a known compound or compound prepared by known method (for example as described in Scheme 3 above) is reacted with NH 4 OH, a known compound, optionally in an organic solvent such as acetonitrile, and the like, to yield the corresponding compound of formula (XlII).
- the compound of formula (XIII) is reacted with a suitably selected reducing agent, such as LAH, and the like, and the like, in an organic solvent such as THF, diethyl ether, and the like, to yield the corresponding compound of formula (Xa).
- a suitably selected reducing agent such as LAH, and the like, and the like
- organic solvent such as THF, diethyl ether, and the like
- a suitably substituted compound of formula (XIV) a known compound or compound prepared by known methods, is reacted with NH 4 OH, in the presence of a coupling agent such as DCC, and the like, optionally in an organic solvent such as acetonitrile, and the like, to yield the corresponding compound of formula (XV).
- the compound of formula (XV) is reacted with a suitably selected reducing agent, such as LAH, and the like, in an organic solvent such as THF, diethyl ether, and the like, to yield the corresponding compound of formula (Xb).
- a suitably selected reducing agent such as LAH, and the like
- organic solvent such as THF, diethyl ether, and the like
- a suitably substituted compound of formula (XVI) wherein J 1 is a suitable leaving group such as Br, Cl, I, tosyl, mesyl, triflyl, and the like a known compound or compound prepared by known methods (for example, by activating the corresponding compound wherein J 1 is OH), is reacted with a cyanide such as potassium cyanide, sodium cyanide, and the like, in an organic solvent such as DMSO, DMF, THF, and the like, to yield the corresponding compound of formula (XVII).
- a cyanide such as potassium cyanide, sodium cyanide, and the like
- the compound of formula (XVII) is reduced according to known methods, for example by reacting with a suitable reducing agent such as LAH, borane, and the like, to yield the corresponding compound of formula (Xc).
- a suitable reducing agent such as LAH, borane, and the like
- a suitably substituted compound of formula (XVIII) a known compound or compound prepared by known methods is activated, according to known method, to yield the corresponding compound of formula (XIX), wherein J 2 is a suitable leaving group, such tosylate, Cl, Br, I, mesylate, triflate, and the like.
- the compound of formula (XIX) is reacted with a phthalimide salt such as potassium phthlimide, sodium phthalimide, and the like, in an organic solvent such as DMF, DMSO, acetonitrile, and the like, preferably, at an elevated temperature in the range of from 50 0 C to about 200°C, more preferably, w at about reflux temperature, to yield the corresponding compound of formula (XX).
- a phthalimide salt such as potassium phthlimide, sodium phthalimide, and the like
- organic solvent such as DMF, DMSO, acetonitrile, and the like
- the compound of formula (XX) is reacted with N 2 H 4 , a known compound, in an organic solvent such as ethanol, methanol, and the like, preferably, at an elevated temperature in the range of from about 50 0 C to about 100 0 C, more preferably, at about reflux temperature, and the like, to yield the corresponding compound of formula (Xd).
- reaction step of the present invention may be carried out in a variety of solvents or solvent systems, said reaction step may also be carried out in a mixture of the suitable solvents or solvent systems.
- the processes for the preparation of the compounds according to the invention give rise to mixture of stereoisomers
- these isomers may be separated by conventional techniques such as preparative chromatography.
- the compounds may be prepared in racemic form, or individual enantiomers may be prepared either by enantiospecific synthesis or by resolution.
- the compounds may, for example, be resolved into their component enantiomers by standard techniques, such as the formation of diastereomeric pairs by salt formation with an optically active acid, such as (-)-di-p-toluoyl-D-tartaric acid and/or (+)-di-p-toluoy!-L-tartaric acid followed by fractional crystallization and regeneration of the free base.
- the compounds may also be resolved by formation of diastereomeric esters or amides, followed by chromatographic separation and removal of the chiral auxiliary. Alternatively, the compounds may be resolved using a chiral HPLC column.
- any of the processes for preparation of the compounds of the present invention it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in Protective Groups in Organic Chemistry, ed. J.F.W. McOmie, Plenum Press, 1973; and T.W. Greene & P.G.M. Wuts, Protective Groups in Organic Synthesis. John Wiley & Sons, 1991.
- the protecting groups may be removed at a convenient subsequent stage using methods known from the art.
- the present invention further comprises pharmaceutical compositions containing one or more compounds " of formula (I) with a pharmaceutically acceptable carrier.
- Pharmaceutical compositions containing one or more of the compounds of the invention described herein as the active ingredient can be prepared by intimately mixing the compound or compounds with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques.
- the carrier may take a wide variety of forms depending upon the desired route of administration (e.g., oral, parenteral).
- suitable carriers and additives include water, glycols, oils, alcohols, flavoring agents, preservatives, stabilizers, coloring agents and the like;
- suitable carriers and additives include starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents and the like.
- Solid oral preparations may also be coated with substances such as sugars or be enteric-coated so as to modulate major site of absorption.
- the carrier will usually consist of sterile water and other ingredients may be added to increase solubility or preservation.
- injectable suspensions or solutions may also be prepared utilizing aqueous carriers along with appropriate additives.
- compositions of this invention one or more compounds of the present invention as the active ingredient is intimately admixed with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques, which carrier may take a wide variety of forms depending of the form of preparation desired for administration, e.g., oral or parenteral such as intramuscular.
- a pharmaceutical carrier may take a wide variety of forms depending of the form of preparation desired for administration, e.g., oral or parenteral such as intramuscular.
- any of the usual pharmaceutical media may be employed.
- suitable carriers and additives include water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like;
- suitable carriers and additives include starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents and the like. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. If desired, tablets may be sugar coated or enteric coated by standard techniques.
- the carrier will usually comprise sterile water, through other ingredients, for example, for purposes such as aiding solubility or for preservation, may be included.
- injectable suspensions may also be prepared, in which case appropriate liquid carriers, suspending agents and the like may be employed.
- the pharmaceutical compositions herein will contain, per dosage unit, e.g., tablet, capsule, powder, injection, teaspoonful and the like, an amount of the active ingredient necessary to deliver an effective dose as described above.
- compositions herein will contain, per unit dosage unit, e.g., tablet, capsule, powder, injection, suppository, teaspoonful and the like, of from about 0.1-1000 mg and may be given at a dosage of from about 0.01-200.0 mg/kg/day, preferably from about 0.1 to 100 mg/kg/day, more preferably from about 0.5-50 mg/kg/day, more preferably from about 1.0-25.0 mg/kg/day or any range therein.
- the dosages may be varied depending upon the requirement of the patients, the severity of the condition being treated and the compound being employed. The use of either daily administration or post- periodic dosing may be employed.
- compositions are in unit dosage forms from such as tablets, pills, capsules, powders, granules, sterile parenteral solutions or suspensions, metered aerosol or liquid sprays, drops, ampoules, autoinjector devices or suppositories; for oral parenteral, intranasal, sublingual or rectal administration, or for administration by inhalation or insufflation.
- the composition may be presented in a form suitable for once-weekly or once- monthly administration; for example, an insoluble salt of the active compound, such as the decanoate salt, may be adapted to provide a depot preparation for intramuscular injection.
- a pharmaceutical carrier e.g.
- preformulation compositions containing a homogeneous mixture of a compound of the present - invention, or a pharmaceutically acceptable salt thereof.
- preformulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective dosage forms such as tablets, pills and capsules.
- This solid preformulation composition is then subdivided into unit dosage forms of the type described above containing from 0.1 to about 1000 mg of the active ingredient of the present invention.
- the tablets or pills of the novel composition can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action.
- the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former.
- the two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release.
- enteric layers or coatings such materials including a number of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate.
- liquid forms in which the novel compositions of the present invention may be incorporated for administration orally or by injection include, aqueous solutions, suitably flavored syrups, aqueous or oil suspensions, and flavored emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil or peanut oil, as well as elixirs and similar pharmaceutical vehicles.
- Suitable dispersing or suspending agents for aqueous suspensions include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, polyvinylpyrrolidone or gelatin.
- the method of treating depression described in the present invention may also be carried out using a pharmaceutical composition comprising any of the compounds as defined herein and a pharmaceutically acceptable carrier.
- the pharmaceutical composition may contain between about 0.1 mg and 1000 mg, preferably about 50 to 500 mg, of the compound, and may be constituted into any form suitable for the mode of administration selected.
- Carriers include necessary and inert pharmaceutical excipients, including, but not limited to, binders, suspending agents, lubricants, flavorants, sweeteners, preservatives, dyes, and coatings.
- compositions suitable for oral administration include solid forms, such as pills, tablets, caplets, capsules (each including immediate release, timed release and sustained release formulations), granules, and powders, and liquid forms, such as solutions, syrups, elixers, emulsions, and suspensions.
- forms useful for parenteral administration include sterile solutions, emulsions and suspensions.
- compounds of the present invention may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three or four times daily.
- compounds for the present invention can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal skin patches well known to those of ordinary skill in that art.
- the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen.
- the active drug component can be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like.
- suitable binders include, without limitation, starch, gelatin, natural sugars such as glucose or beta- lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like.
- Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum and the like.
- the liquid forms in suitably flavored suspending or dispersing agents such as the synthetic and natural gums, for example, tragacanth, acacia, methyl- cellulose and the like.
- suspending or dispersing agents such as the synthetic and natural gums, for example, tragacanth, acacia, methyl- cellulose and the like.
- sterile suspensions and solutions are desired.
- Isotonic preparations which generally contain suitable preservatives are employed when intravenous administration is desired.
- Compounds of this invention may be administered in any of the foregoing compositions and according to dosage regimens established in the art whenever treatment of depression is required.
- the daily dosage of the products may be varied over a wide range from 0.01 to 200 mg / kg per adult human per day.
- the compositions are preferably provided in the form of tablets containing, 0.01 , 0.05, 0.1 , 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0, 50.0, 100, 150, 200, 250, 500 and 1000 milligrams of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated.
- An effective amount of the drug is ordinarily supplied at a dosage level of from about 0.01 mg/kg to about 200 mg/kg of body weight per day.
- the range is from about 0.1 to about 100.0 mg/kg of body weight per day, more preferably, from about 0.5 mg/kg to about 50 mg/kg, more preferably, from about 1.0 to about 25.0 mg/kg of body weight per day.
- the compounds may be administered on a regimen of 1 to 4 times per day. 5
- Optimal dosages to be administered may be readily determined by those skilled in the art, and will vary with the particular compound used, the mode of administration, the strength of the preparation, the mode of administration, and the advancement of the disease condition. In addition, factors associated with the 10 particular patient being treated, including patient age, weight, diet and time of administration, will result in the need to adjust dosages.
- Catechol (10.26 g, 93.2 mmol), sodium methoxide (25% by weight in methanol, 40.3 g, 186 mmol), and methyl dichloroacetate (13.3 g, 93.2 mmol) were combined in dry methanol (100 mL). The solution was heated to reflux overnight. The reaction was cooled to room temperature, acidified by addition of concentrated hydrophloric acid and then reduced in volume under vacuum to about 50 mL. Water was added and the mixture was extracted with diethyl ether (3 x 100 ml_).
- Benzo[1 ,3]dioxole-2-carboxylic acid amide (5.44 g, 32.9 mmol) was dissolved in tetrahydrofuran (THF, 100 mL). Lithium aluminum hydride (LAH, 1 M in THF, 39.5 mL, 39.5 mmol) was added slowly to the solution at room temperature. The reaction was stirred at room temperature for 24 hours. Distilled water was added to destroy the excess LAH. Aqueous sodium hydroxide (3.0 M, 100 mL) was added ahd the solution was extracted with ethyl acetate (3 x 100 mL). The combined organic solution was washed with water and dried over MgSO 4 . The solvent was evaporated to yield C- benzo[1 ,3]dioxol-2-yl-methylamine as a colorless oil. MS (ESI): 152.1 (M+H+)
- the white solid was combined with potassium phthalimide (14.4 g, 78 mmol) in DMF (250 mL) and heated to reflux for 1 h, cooled to room temperature and poured into vigorously stirring water (1.5 L) and stirred 30 min. White solid was filtered and the solid was washed several times with water, 2% NaOH, and water again and let air dry to yield a (2S)-2-(2,3-Dihydro- benzo[1 ,4]dioxin-2-ylmethyl)-isoindole-1 ,3-dione as white powdery solid.
- Racemic 2,3-dihydro-1 ,4-benzdioxin-2-ylmethylamine (8.25 g, 5.0 mmol) and tri ⁇ thylannine (1.52 g, 15 mmol) were combined in DMF (10 ml_) and cooled in an ice bath as dimethylsulfamoyl chloride (1.44 g, 10 mmol) was added. The reaction mixture was then stirred for 3 hr with continued cooling. The reaction mixture was partitioned between ethyl acetate and water, and the ethyl acetate solution was washed with brine, dried (MgSC ⁇ i) and evaporated in vacuo to yield an oil.
- Racemic 2,3-dihydro-1 ,4-benzdioxin-2-ylmethylamine (825 mg, 5 mmol) was dissolved in ethyl formate (15 ml_), refluxed for 30 min and evaporated in vacuo to yield N-(2,3-dihydro-benzo[1 ,4]dioxin-2-ylmethyl)-formamide as an oil.
- the DCM was separated and the aqueous phase extracted twice with DCM.
- the combined DCM phase was dried (Na 2 SO 4 ) and evaporated in vacuo to yield an oil, which was purified with flash column chromatography (ethyl acetate) to yield an oil.
- reaction mixture was diluted with diethyl ether and 1 N HCI (750 mL) and the organic layer was separated and washed 2 times with 1 N HCi (250 mL), once with water (150 mL), twice with brine, dried (MgSO 4 ) and evaporated in vacuo to yield light yellow solid of toluene-4-sulfonic acid (2S)-6,7-dichloro-2,3-dihydro-benzo[1 ,4]dioxin-2- ylmethyl ester.
- 2-ylmethyl ester (8.0 g, 20.5 mmol) was combined with potassium phthalimide (6.1 g, 33 mmol) in DMF (75 mL) and heated to reflux for 1 h, cooled to room temperature and poured into vigorously stirring water (0.5 L) and then stirred 30 min. White solid was filtered and the solid was washed several times with water, 2% NaOH, and water again and then let air dry to yield (2S)-2-(6,7- dichloro-2,3-dihydro-benzo[1 ,4]dioxin-2-ylmethyl)-isoindole-1 ,3-dione (6.0 g, 80%) as a white powdery solid.
- Example 4 Title compound was prepared according to the procedure described in Example 4 above, starting with 4-methylcatechol, to yield a white solid, which was recrystallized from ethyl acetate/ hexane to yield the title compound as a white solid.
- DSR Dominant-Submissive Relations
- RDBM Behavior Model
- RSBM Submissive Behavior Model
- mice Male Sprague Dawley rats (140 to 16Og) from Charles River Laboratories Wilmington, MA were used in this assay. Shipments of rats were received at two-week intervals. Each shipment went through five-day quarantine, one-week acclimation period, and one-week selection process, followed by five-weeks of drug or vehicle treatment to those pairs selected.
- Rats were housed four per cage. Access to food was restricted to one hour per day after testing on Monday through Thursday. After testing on Friday, rats had free access to food until being fasted again on Sunday. At no time were the rats deprived of water. The food deprivation periods used had little effect on weight gain as the average weight of rats was about 30Og at the end of the study. At the conclusion of experiment rats were sacrificed by decapitation, the trunk blood and brains were collected for in vitro experiments and drug concentration measurements.
- the basic testing apparatus consisted of two chambers connected with a tunnel only large enough to allow one rat to pass through at a time. On the floor, at the mid-point of the tunnel was a container of sweetened milk.
- This basic apparatus was replicated, so that a total of four pairs of rats can be video tracked simultaneously.
- the camera can distinguish rats marked by different colors.
- the rats' heads were colored for the purpose of video tracking, red in one cage and yellow in the other cage. Only one animal at a time can have comfortable access to the feeder, but both animals can drink milk during the five-minute daily session.
- time spent in the feeder zone by each rat was recorded by the video tracking software and saved into a text file.
- the test began with a random assignment of rats into pairs. Each member of a pair was placed in an opposite chamber of the testing apparatus. The time spent in the feeder zone by each animal was recorded. During the first week (five days) of testing the animals habituate to the new environment. Dominance was assigned to the animal with the highest score during the second week of testing if three criteria were achieved. First, there must have been a significant difference (two-tailed t-test, P ⁇ 0.05) between the average daily drinking scores of both animals. Second, the dominant animal score must have been at least 25% greater than the submissive animal's score. Finally, there must have been no "reversals" during the pair selection week where the putative submissive rat out-scored its dominant partner on isolated occasions. Ideally there were minimal reversals during the acclimation week as well. About twenty-five to thirty-three percent of the initial animal pairs achieved these criteria and only these pairs were continued in the study.
- Terminal blood samples (0.5-1.0 ml_) were collected post experiment into heparinized tubes. Blood samples were centrifuged for cell removal, and 200 ⁇ l_ of plasma supernatant was then transferred to a clean vial, placed on dry ice, and subsequently stored in a -80 0 C freezer prior to analysis. Two hundred microliters of acetonitrile containing internal standard was added to 100 ⁇ L of plasma or brain tissue to precipitate proteins and/or tissue residues. Samples were centrifuged and supernatant removed for analysis by liquid chromatography-triple quadruple mass spectrometry (LC-MS-MS). Calibration standards were prepared by adding appropriate volumes of stock solution directly into blank plasma or brain tissue homogenates and treated identically to collected samples. Calibration standards were prepared in the range of 0.01 to 10 ⁇ M for quantitation. LC-ESI-MS/MS (negative mode) analysis was performed utilizing multiple reaction monitoring (MRM) for detection of characteristic ions for the test compound.
- MRM multiple reaction
- Dominance Level (week n in %) (Dominance Level (week n)) / (Dominance Level (week 2)
- the normalized DL values were used for this calculation, where DL values for treatment weeks were normalized as a percent of the second week (pretreatment) value of that pair according the above formula.
- the minimum of the response determined drug positive activity, corresponding to efficacy, since DL values were always reduced if the response to a drug was positive.
- DL values were increased. If the drug did not have such activity the maximum of the response did not exceed 100%. Any maximal DL value significantly higher then control value (about 100%) indicated drug negative activity.
- Compound #8 was evaluated in the Rat Reduction of Submissive Behavior Model (RSBM) of depression (Malatynska, E., Rapp, R., Harrawood, D., and Tunnicliff, G., Neuroscience and Biobehavioral Review, 82 (2005) 306- 313; Malatynska, E., and Knapp, RJ. , Neuroscience and Biobehavioral Review. 29 (2005) 715-737).
- RSBM Submissive Behavior Model
- Compound #8 was observed to reduce submissive behavior in a dose-dependent manner.
- Dominance Level (DL) values in the group of submissive rats treated with 2.5 mg/kg dose of Compound #8 did not significantly differ from control. However, the group treated with Compound #8 at 12.0 mg/kg showed DL values significantly different from vehicle treated controls after the second, fourth and fifth week of treatment. Similarly, the group treated with Compound #8 at 60 mg/kg showed a significant difference in DL values relative to vehicle starting at the first week and continuing through the treatment duration of 5 weeks. At the highest dose, (120 mg/kg) Compound #8 DL values were significantly different from the control group after first week, however, this significance dissipated after the second week of treatment. Fluoxetine treated animals (10 mg/kg) consistently showed increased submissiveness during first week of treatment.
- the activity onset time was estimated from the non-linear regression fit.
- the non-linear regression model was fit for each drug and dose normalized daily DL values.
- Activity Onset Time at the 50% effect (AOT50) and Emax for Compound #8 at 2.5 mg/kg, 12 mg/kg and 60 mg/kg was 2.1 ; 5.3 and 1.6 days, respectively and was not significantly different between doses.
- the maximum of the effect derived from this analysis was 52.4 ⁇ 32.7% (SEM), 87.9 ⁇ 42.6% (SEM) and 116.9 ⁇ 29.5% (SEM) for the 2.5 mg/kg, 12 mg/kg and 60 mg/kg dose respectively and was also not significantly different between these doses.
- mice are suspended by their tails to a metal or plastic rod using clip or scotch tape.
- the test is usually quite short, 5-7 min, and the amount of time the mice spend immobile is recorded either manually or with an automated device.
- Agents which have antidepressant activity decrease the duration of immobility of mice in this test.
- the basic apparatus for the tail suspension assay consisted of a yellow plastic chamber (91 x 45 x 10 cm) divided for four arenas 25, 20, 20 and 25 cm wide separated by yellow plastic walls 0.75 cm thick. Mice were suspended by their tails using a rubber clip (7 cm long) attached to the plastic rod that was placed on the top of a testing chamber half way through its deep dimension. Each experimental session was videotaped and analyzed for four animals in the real time by computer software ("Depression Scan" Clever Sys Inc.). The computer justification of immobility was calibrated with the use of animals dosed with lorazepam while justification of movement was calibrated with the high dose of desipramine treated animals. Control, vehicle treated animals and animals treated with Compound #8 were analyzed under the calibrated settings. The settings were adjusted separately for dark (CH3/HeJ and C57BI/6J strains) and white mice (Balb/cJ and A/J strains). A yellow background was used for dark mice and a blue background was used to record movements of white mice.
- test compound The ability of a test compound to decrease the duration of immobility, or increase mobility was measured using the TST procedure described above.
- the dose-response for different antidepressants and Compound #8 in the ChVHeJ mice was evaluated.
- Compound #8 was suspended in 0.5% of methylcellulose.
- Positive controls included duloxetine (DLX), venlafaxine (VLX)and desipramine (DMI) which were dissolved in 0.5% methylcellulose and lorazepam (LOR) which was suspended in 0.5% of methylcellulose in water by sonication. All drugs and vehicles were administered orally (p.o.) by gavage in a volume of 10 mL/kg.
- mice were ordered 5 weeks old and at the beginning of experiment their weight was 20 ⁇ 5g.
- Animals were housed in groups of four in plastic cages at an ambient temperature of 21 0 C to 23°C with an automated 12/12 hours light/dark cycle and access to water and a commercial rodent food ad libitum.
- This group was divided into eight experiments testing the effects of Compound #8, positive controls (DMI, VLX, DLX) at different doses and negative control (LOR) at 5 mg/kg.
- Each experiment consisted of seven treatment groups with four animals per group. A total of 28 animals per experiment were used. Every two consecutive experiments (1 & 2, 3 & 4, 5 & 6 and 7 & 8) were exact replicas of each other. This resulted in a total number of eight animals per treatment group at the end of the study.
- One treatment group of four animals in each experiment was a vehicle treated group. In addition to the vehicle treated group, the effects of DMI at 6 mg/kg, 12 mg/kg, 30 mg/kg, 60 mg/kg and 120 mg/kg and LOR at 5 mg/kg were tested in experiments 1 and 2.
- Compound #8 and all tested antidepressant drugs decreased immobility time and increased mobility time in CH3/HeJ mice during a 7-min testing session.
- Compound #8 effects were statistically significant at 12 mg/kg, 60 mg/kg, and 120 mg/kg. Significance was determined in comparison to parallel controls treated with vehicle.
- DMI effects were statistically significant at 12, 30, 60 and 120 mg/kg.
- VLX effects were statistically significant at 6, 12, 30, 60 and 120 mg/kg.
- DLX effects were statistically significant at 60 and 120 mg/kg.
- ED 5 O and E max values were calculated from these results by non-linear regression analysis.
- ED 50 and Em 3x values are listed in Table 3 below.
- ED 50 values calculated for immobility and mobility were not significantly different across treatments.
- the ED 50 value for Compound #8 was significantly lower than the ED 50 value for DLX but not different than the ED 50 values for DMI and VLX.
- the Emax values calculated for immobility and mobility were not significantly different for Compound #8 but were significantly different for all tested antidepressant.
- the E ma ⁇ immobility value for Compound #8 was also significantly lower then than antidepressant drug values.
- Example 15 - Forced Swim Test (Acute) The Forced Swim test (FST) is a commonly used procedure to screen compounds for possible antidepressant properties. This test is also known as the behavioral despair test. Rodents placed in familiar tanks filled with water present a wide variety of escape or immobility behaviors. Antidepressant drugs from different classes markedly increase escape behaviors and/or decrease latency or duration of immobility. Since these effects are characteristic of clinically active antidepressants the compounds with unknown clinical activity showing such effects in the FST are interpreted to have potential to treat human mood disorders.
- mice Male Sprague Dawley rats (140 to 160 g) from Charles River Laboratories Wilmington, MA were used. The animals went through a five-day quarantine period before being subjected to the experimental procedure. Animals were housed in groups of four in plastic cages at an ambient temperature of 21 0 C to 23°C with an automated 12 hour light/dark cycle and access to water and commercial rodent food ad libitum. Animals were not handled more than for the routine bedding change prior to pre-test swirn session.
- Each experiment consisted of seven treatment groups with n 4 animals per group. A total of 28 animals per experiment were used. Two consecutive experiments (1 and 2, 3 and 4, and 5 and 6) were exact replicas of each other. This resulted in a total number of eight animals per treatment group at the end of the study.
- One treatment group of n 4 animals in each experiment was a vehicle treated group.
- the basic apparatus consisted of a cylinder (46 cm tall x -20 cm diameter) filled with water to 30 cm deep, at a temperature of 25 ⁇ 1 0 C.
- the automated version of the FST was used to perform the experiments.
- Plumbing for automatic filling and emptying water connected the four cylinders. Cylinders were placed in the dividing chambers 25 cm wide to separate animals visually.
- Each 5-minute experimental session was videotaped and analyzed in real time by computer software (Clever Systems, Inc.) for four animals at a time. The immobility, swimming, climbing and escape times were recorded by the software. The four activities are defined as follow.
- Immobility the animal floats motionlessly or makes only those movements necessary to keep its head above water; Climb: the animal vigorously moves vertically while scratching the wall around the cylinder; Swim: the animal moves horizontally around in the cylinder more than necessary to keep its head above water; and Escape: sum of all vigorous active movements.
- test compound The ability of a test compound to decrease the duration or frequency of immobility, or changes in swimming, climbing and escape times, was measured using the FST procedure described above.
- Clinically effective antidepressants and/or novel compounds that have potential antidepressant properties decrease the duration or frequency of immobility in the FST when administered between the pre-test and the test sessions.
- the analysis of the results in the studies described was focused on the immobility time during 5-minute test session.
- mice were pre-treated with a vehicle or test compound after completing the pre-test swim session, then 24 hours later and then shortly prior to the 5-minute test session; i.e., three injections were given to each animal between the two swim sessions that occurred on 3 consecutive days.
- the time prior to test session was 1 hour for desipramine, maprotyline, venlafaxine, Jorazepam or 4 hours for Compound #8; the time of the maximal effect in the maximal electroshock seizures (MES) test.
- MES maximal electroshock seizures
- Data were analyzed using GraphPad Prism software (GraphPad Software, Inc. San Diego, CA). For the comparison of the effect of different doses for various drugs on immobility in the FST one-way ANOVA was used followed by Dunnett's multiple comparison test.
- the ED 50 and E ma ⁇ values were calculated for desipramine and Compound #8 using non-linear regression analysis with a one-phase exponential decay equation for curve fitting.
- the ED50 and E max values were statistically compared using two-tail t-test.
- the desipramine effect was statistically significant at 6 mg/kg, 12 mg/kg, 30 mg/kg, and 60 mg/kg.
- the effect of treatment with Compound #8 was statistically significant at 12 mg/kg, 60 mg/kg, and 120 mg/kg compared to vehicle treated controls. The large variability between individual rats rendered the effect of the 30 mg/kg dose of Compound #8 not significantly different from control.
- the immobility data for 30 mg/kg dose were not used in the ED 50 calculation.
- the ED 50 value for Compound #8 was significantly different from the ED50 value for desipramine at p ⁇ 0.001 (two tail t-test). There was no statistically significant difference between E ma ⁇ values for desipramine and Compound #8.
- Venlafaxine and maprotyline (postive controls) were tested only at three doses of 12 mg/kg, 30 mg/kg, and 60 mg/kg.
- CMS chronic mild stress
- the CMS procedure may serve as a suitable research tool in studies
- the animals were first trained to consume a 1% sucrose solution; training consisted of eight 1 h baseline tests in which sucrose was presented, in the home cage, following 14h food and water deprivation; the sucrose intake
- sucrose consumption was monitored, under similar conditions, at weekly intervals throughout the whole experiment.
- each week of stress regime consisted of: two periods of food or water deprivation, two periods of 45 degree-cage tilt, two periods of intermittent illumination (lights on and off every 2h), two periods of soiled cage (250 ml water in sawdust bedding), one period of paired housing, two periods of low intensity stroboscopic illumination (150 flashes/min), and three periods of no stress. All stressors were 10 - 14 h of duration and were applied individually and continuously, day and night. Control animals were housed in separate rooms and had no contact with the stressed animals. They were deprived of food and water for the 14h preceding each sucrose test, but otherwise food and water were freely available in the home cage.
- vehicle 0.5% methylcellulose, 1 ml/kg
- Compound #8 at 12 mg/kg, 30 mg/kg or 60 mg/kg
- imipramine 10 g/kg or venlafaxine at 10 mg/kg as reference treatments.
- the drugs were administered at approx. 10.00 and the weekly sucrose tests were carried out 24h following the last drug injections. After five weeks all treatments were terminated and 24h later the blood and/or brain samples were collected from all animals and submitted for further biochemical analysis. Stress was continued throughput the entire period of treatment.
- Trunk blood for plasma was collected into EDTA tubes which contained EDTA (approximately 1.6mg/ml of blood). The EDTA blood was centrifuged directly at 1500 xg for 10 min at 4°C. The plasma was aspirated and stored in Eppendorf tubes at -70 0 C.
- Example 17 Resident / Intruder Assay (also known as Chronic Social Stress Assay)
- the behavioral resident / intruder assay is used to screen compounds for anti-depressant-like activity.
- Compound #8 was tested in this assay, with the assay run according to the procedure as described in Rygula, R., Abumaria, N., Ftugge, G., Fuchs, E., Ruther, E., Havemann-Reinecke, U., Behavioral Brain Research, 162 (2005), pp127-134.
- Tables 5, 6 and 7 below list the mean and standard deviation values for measured parameters, for the following compounds, administered p.o. (orally): vehicle, control compounds imipramine at 10 mg/kg and venlafaxine at 10 mg/kg, Compound #8 at 60 mg/kg and Compound #8 at 120 mg/kg.
- Imipramine - stressed 10 70.5 ⁇ 19.5 78.3 ⁇ 15.1 73.6. ⁇ 19.4
- Venlafaxine - stressed 10 74.5 + 16.7 76.1 ⁇ 18.2 73.3 ⁇ 17.6
- Compound #8 was active in the resident / intruder assay indicating that Compound #8 would be expected to be active as an anti-depressant.
- Compound #8 prepared as in Example 7 is formulated with sufficient finely divided lactose to provide a total amount of 580 to 590 mg to fill a size O hard gel capsule.
Abstract
Description
Claims
Priority Applications (17)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK06847799.1T DK1973539T3 (en) | 2005-12-19 | 2006-12-19 | Use of benzo-condensed heterocyclic sulfamide derivatives for the treatment of depression |
EA200870090A EA015392B1 (en) | 2005-12-19 | 2006-12-19 | Method for treatment of depression |
DE602006013883T DE602006013883D1 (en) | 2005-12-19 | 2006-12-19 | USE OF BENZO-CONDENSED HETEROCYCLIC SULPHAMIDE DERIVATIVES FOR THE TREATMENT OF DEPRESSIONS |
EP06847799A EP1973539B1 (en) | 2005-12-19 | 2006-12-19 | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression |
PL06847799T PL1973539T3 (en) | 2005-12-19 | 2006-12-19 | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression |
JP2008547471A JP5190376B2 (en) | 2005-12-19 | 2006-12-19 | Use of benzo-fused heterocyclic sulfamide derivatives to treat depression |
NZ569045A NZ569045A (en) | 2005-12-19 | 2006-12-19 | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression |
KR1020087017574A KR101415532B1 (en) | 2005-12-19 | 2006-12-19 | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression |
AT06847799T ATE464895T1 (en) | 2005-12-19 | 2006-12-19 | USE OF BENZOCONDENSED HETEROCYCLIC SULFAMIDE DERIVATIVES FOR THE TREATMENT OF DEPRESSION |
AU2006331733A AU2006331733B2 (en) | 2005-12-19 | 2006-12-19 | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression |
BRPI0620014-1A BRPI0620014A2 (en) | 2005-12-19 | 2006-12-19 | use of benzofused heterocycle sulfamide derived compounds for the treatment of depression |
CA2634112A CA2634112C (en) | 2005-12-19 | 2006-12-19 | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression |
SI200630723T SI1973539T1 (en) | 2005-12-19 | 2006-12-19 | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression |
CN2006800524068A CN101336106B (en) | 2005-12-19 | 2006-12-19 | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression |
IL192103A IL192103A (en) | 2005-12-19 | 2008-06-12 | Benzo-fused heterocycle sulfamide derivatives for use in the treatment of depression |
NO20083036A NO20083036L (en) | 2005-12-19 | 2008-07-04 | Use of benzofused heterocyclic sulfamide derivatives for the treatment of depression |
HK09102822.1A HK1125040A1 (en) | 2005-12-19 | 2009-03-24 | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75173005P | 2005-12-19 | 2005-12-19 | |
US60/751,730 | 2005-12-19 | ||
US11/612,249 | 2006-12-18 | ||
US11/612,249 US20070155827A1 (en) | 2005-12-19 | 2006-12-18 | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007075751A1 true WO2007075751A1 (en) | 2007-07-05 |
Family
ID=38007055
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/048538 WO2007075751A1 (en) | 2005-12-19 | 2006-12-19 | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression |
Country Status (26)
Country | Link |
---|---|
US (1) | US20070155827A1 (en) |
EP (1) | EP1973539B1 (en) |
JP (1) | JP5190376B2 (en) |
KR (1) | KR101415532B1 (en) |
CN (1) | CN101336106B (en) |
AT (1) | ATE464895T1 (en) |
AU (1) | AU2006331733B2 (en) |
BR (1) | BRPI0620014A2 (en) |
CA (1) | CA2634112C (en) |
CR (1) | CR10165A (en) |
CY (1) | CY1110669T1 (en) |
DE (1) | DE602006013883D1 (en) |
DK (1) | DK1973539T3 (en) |
EA (1) | EA015392B1 (en) |
ES (1) | ES2342846T3 (en) |
HK (1) | HK1125040A1 (en) |
IL (1) | IL192103A (en) |
MY (1) | MY148459A (en) |
NI (1) | NI200800176A (en) |
NO (1) | NO20083036L (en) |
NZ (1) | NZ569045A (en) |
PL (1) | PL1973539T3 (en) |
PT (1) | PT1973539E (en) |
SI (1) | SI1973539T1 (en) |
SV (1) | SV2009002861A (en) |
WO (1) | WO2007075751A1 (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009120189A1 (en) * | 2008-03-26 | 2009-10-01 | Janssen Pharmaceutica N.V. | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of anxiety |
WO2010008776A3 (en) * | 2008-06-23 | 2011-04-07 | Janssen Pharmaceutica Nv | Crystalline form of (2s)-(-)-n-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide |
US8084490B2 (en) | 2004-06-16 | 2011-12-27 | Janssen Pharmaceutica N.V. | Sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders |
US8283478B2 (en) | 2005-05-20 | 2012-10-09 | Janssen Pharmaceutica Nv | Process for preparation of sulfamide derivatives |
US8497298B2 (en) | 2005-12-19 | 2013-07-30 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels |
US8691867B2 (en) | 2005-12-19 | 2014-04-08 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction |
US8815939B2 (en) | 2008-07-22 | 2014-08-26 | Janssen Pharmaceutica Nv | Substituted sulfamide derivatives |
US8853263B2 (en) | 2006-05-19 | 2014-10-07 | Janssen Pharmaceutica Nv | Co-therapy for the treatment of epilepsy and related disorders |
US8937096B2 (en) | 2005-12-19 | 2015-01-20 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090247616A1 (en) * | 2008-03-26 | 2009-10-01 | Smith-Swintosky Virginia L | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of anxiety |
US20090247617A1 (en) * | 2008-03-26 | 2009-10-01 | Abdel-Magid Ahmed F | Process for the preparation of benzo-fused heteroaryl sulfamates |
JP2011519839A (en) * | 2008-04-29 | 2011-07-14 | エヌエスエイビー、フィリアル アヴ ノイロサーチ スウェーデン エービー、スヴェーリエ | Modulator of dopamine neurotransmission |
CN102015674B (en) * | 2008-04-29 | 2014-10-29 | Nsab神经研究瑞典公司分公司 | Modulators of dopamine neurotransmission |
AU2009242092A1 (en) * | 2008-04-29 | 2009-11-05 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Modulators of dopamine neurotransmission |
AU2012314317A1 (en) | 2011-09-29 | 2014-04-03 | Janssen Pharmaceutica Nv | Improved process for the preparation of sulfamide derivatives |
KR20140082736A (en) | 2011-09-29 | 2014-07-02 | 얀센 파마슈티카 엔.브이. | Process for the preparation of sulfamide derivatives |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002009694A1 (en) * | 2000-08-02 | 2002-02-07 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful for the treatment of depression |
WO2006007435A1 (en) * | 2004-06-16 | 2006-01-19 | Janssen Pharmaceutica, N.V. | Sulfamate and sulfamide derivatives for the treatment of epilepsy and related disorders |
Family Cites Families (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2527861A (en) * | 1948-05-07 | 1950-10-31 | Monsanto Chemicals | Mono alkyl sulfamides |
BE636655A (en) * | 1962-09-14 | |||
US3318952A (en) * | 1964-01-22 | 1967-05-09 | Sandoz Ag | Dibenzylsulfamides |
US3383414A (en) * | 1964-08-26 | 1968-05-14 | Sandoz Ag | Benzocycloalkyl sulfamides |
US3539573A (en) * | 1967-03-22 | 1970-11-10 | Jean Schmutz | 11-basic substituted dibenzodiazepines and dibenzothiazepines |
US3621096A (en) * | 1969-04-03 | 1971-11-16 | Univ North Carolina | Antidepressant method and composition for same comprising a tricyclic antidepressant and a thyroid hormone |
US3689669A (en) * | 1970-10-09 | 1972-09-05 | Univ Of North Carolina The | Antidepressant method and composition |
US5212326A (en) * | 1979-08-20 | 1993-05-18 | Abbott Laboratories | Sodium hydrogen divalproate oligomer |
FR2479825A1 (en) * | 1980-04-04 | 1981-10-09 | Fabre Sa Pierre | BENZODIOXAN 1,4 METHOXY-2 PROPANOLAMINES, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS |
US4513006A (en) * | 1983-09-26 | 1985-04-23 | Mcneil Lab., Inc. | Anticonvulsant sulfamate derivatives |
US4804663A (en) * | 1985-03-27 | 1989-02-14 | Janssen Pharmaceutica N.V. | 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
IE58370B1 (en) * | 1985-04-10 | 1993-09-08 | Lundbeck & Co As H | Indole derivatives |
GB8607684D0 (en) * | 1986-03-27 | 1986-04-30 | Ici America Inc | Thiazepine compounds |
US4831031A (en) * | 1988-01-22 | 1989-05-16 | Pfizer Inc. | Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity |
US5158952A (en) * | 1988-11-07 | 1992-10-27 | Janssen Pharmaceutica N.V. | 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use |
US5238945A (en) * | 1989-04-11 | 1993-08-24 | H. Lundbeck A/S | Method of treating psychoses |
GB8908085D0 (en) * | 1989-04-11 | 1989-05-24 | Lundbeck & Co As H | New therapeutic use |
US5194446A (en) * | 1989-06-12 | 1993-03-16 | A. H. Robins Company, Incorporated | Compounds having one or more aminosulfaonyloxy radicals useful as pharmaceuticals |
US5273993A (en) * | 1989-06-12 | 1993-12-28 | A. H. Robins Company, Incorporated | Compounds having one or more aminosulfonyloxy radicals useful as pharmaceuticals |
US5192785A (en) * | 1989-09-03 | 1993-03-09 | A. H. Robins Company, Incorporated | Sulfamates as antiglaucoma agents |
US5229382A (en) * | 1990-04-25 | 1993-07-20 | Lilly Industries Limited | 2-methyl-thieno-benzodiazepine |
IL103172A (en) * | 1991-09-19 | 1997-01-10 | Mcneilab Inc | Preparation of chlorosulfate and sulfamate derivatives of 2, 3:4, 5-bis-o-(1-methylethylidene)-beta-d-fructopyranose and (1-methylcyclohexyl) methanol |
US5242942A (en) * | 1992-04-28 | 1993-09-07 | Mcneilab, Inc. | Anticonvulsant fructopyranose cyclic sulfites and sulfates |
US5258402A (en) * | 1992-06-11 | 1993-11-02 | Mcneil-Ppc, Inc. | Imidate derivatives of pharmaceutically useful anticonvulsant sulfamates |
US5312925A (en) * | 1992-09-01 | 1994-05-17 | Pfizer Inc. | Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride |
US5384327A (en) * | 1992-12-22 | 1995-01-24 | Mcneilab, Inc. | Anticonvulsant sorbopyranose sulfamates |
CA2216648A1 (en) * | 1995-02-15 | 1996-08-22 | Bearsden Bio, Inc. | Alkylcarboxy amino acids-modulators of the kainate receptor |
JP3235448B2 (en) * | 1995-03-24 | 2001-12-04 | ダイソー株式会社 | Method for producing 1,4-benzodioxane derivative |
US5998380A (en) * | 1995-10-13 | 1999-12-07 | New England Medical Center Hospitals, Inc. | Treatment of migraine |
WO1997019682A1 (en) * | 1995-12-01 | 1997-06-05 | Synaptic Pharmaceutical Corporation | Aryl sulfonamide and sulfamide derivatives and uses thereof |
US5753693A (en) * | 1996-06-28 | 1998-05-19 | Ortho Pharmaceutical Corporation | Anticonvulsant derivatives useful in treating manic-depressive bipolar disorder |
UA53655C2 (en) * | 1996-06-28 | 2003-02-17 | Орто-Макнейл Фармасьютікел, Інк. | Method for treating obesity |
US5753694A (en) * | 1996-06-28 | 1998-05-19 | Ortho Pharmaceutical Corporation | Anticonvulsant derivatives useful in treating amyotrophic lateral sclerosis (ALS) |
JP2001500121A (en) * | 1996-08-23 | 2001-01-09 | アルゴス ファーマシューティカル コーポレーション | Anticonvulsants comprising a composition for treating neuropathic pain |
US20020015713A1 (en) * | 1996-10-24 | 2002-02-07 | Murdock Robert W. | Methods and transdermal compositions for pain relief |
US5935933A (en) * | 1997-07-16 | 1999-08-10 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful in treating neuropathic pain |
US5760007A (en) * | 1997-07-16 | 1998-06-02 | Ortho Pharmaceutical Corporation | Anticonvulsant derivatives useful in treating neuropathic pain |
DE69827149T2 (en) * | 1997-08-15 | 2006-03-09 | Fairbanks, Carolyn Ann, Rochester | AGMATIN FOR THE TREATMENT OF NEUROPATHIC PAIN |
US6319903B1 (en) * | 1999-01-19 | 2001-11-20 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful in treating cluster headaches |
HUP0200469A3 (en) * | 1999-02-24 | 2003-03-28 | Univ Cincinnati Cincinnati | Use of sulfamate derivatives for treating impulse control disorders |
CA2369093C (en) * | 1999-04-08 | 2005-10-18 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful in lowering lipids |
CA2369095C (en) * | 1999-04-08 | 2006-07-25 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful in treating chronic neurodegenerative disorders |
WO2001013904A2 (en) * | 1999-08-20 | 2001-03-01 | Ortho-Mcneil Pharmaceutical, Inc. | Composition comprising a tramadol material and an anticonvulsant drug |
US6322503B1 (en) * | 2000-02-17 | 2001-11-27 | G. Roger Sparhawk, Jr. | Method of diagnosing, tracking, and treating depression |
MY126897A (en) * | 2000-07-07 | 2006-10-31 | Ortho Mcneil Pharm Inc | Anticonvulsant derivatives useful for preventing the development of type ii diabetes mellitus and syndrome x |
US7256184B2 (en) * | 2000-10-16 | 2007-08-14 | Rodriguez Victorio C | Treatment of aging disorders in humans |
AU2002240235B2 (en) * | 2001-01-30 | 2006-07-06 | Merck & Co., Inc. | Acyl sulfamides for treatment of obesity, diabetes and lipid disorders |
US6559293B1 (en) * | 2002-02-15 | 2003-05-06 | Transform Pharmaceuticals, Inc. | Topiramate sodium trihydrate |
US8637512B2 (en) * | 2002-07-29 | 2014-01-28 | Glaxo Group Limited | Formulations and method of treatment |
US6949518B1 (en) * | 2003-06-25 | 2005-09-27 | Pao-Hsien Chu | Methods for treating macular degeneration with topiramate |
AR049646A1 (en) * | 2004-06-16 | 2006-08-23 | Janssen Pharmaceutica Nv | USEFUL SULFAMATE AND SULFAMIDE DERIVATIVES FOR THE TREATMENT OF EPILEPSY AND RELATED DISORDERS |
US20060276528A1 (en) * | 2004-08-24 | 2006-12-07 | Abdel-Magid Ahmed F | Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents |
US20060047001A1 (en) * | 2004-08-24 | 2006-03-02 | Parker Michael H | Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents |
MX2007013151A (en) * | 2005-04-22 | 2008-01-16 | Wyeth Corp | Benzodioxane and benzodioxolane derivatives and uses thereof. |
WO2006127184A1 (en) * | 2005-05-20 | 2006-11-30 | Janssen Pharmaceutica N.V. | Process for preparation of sulfamide derivatives |
US20070155824A1 (en) * | 2005-12-19 | 2007-07-05 | Smith-Swintosky Virginia L | Use of benzo-fused heterocycle sulfamide derivatives for disease modification / epileptogenesis |
US8497298B2 (en) * | 2005-12-19 | 2013-07-30 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels |
AR058389A1 (en) * | 2005-12-19 | 2008-01-30 | Janssen Pharmaceutica Nv | USE OF SULFAMIDE BENZO-FUSED HETEROCICLIC DERIVATIVES FOR THE TREATMENT OF OBESITY |
US8716231B2 (en) * | 2005-12-19 | 2014-05-06 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain |
US8937096B2 (en) * | 2005-12-19 | 2015-01-20 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder |
KR101174777B1 (en) * | 2005-12-27 | 2012-08-20 | 엘지디스플레이 주식회사 | Patterning Method and Method of manufacturing Liquid Crystal Display Device using the same |
US20070293476A1 (en) * | 2006-05-19 | 2007-12-20 | Smith-Swintosky Virginia L | Co-therapy for the treatment of epilepsy and related disorders |
AU2007253814A1 (en) * | 2006-05-19 | 2007-11-29 | Janssen Pharmaceutica N.V. | Co-therapy for the treatment of epilepsy |
EP2238122A1 (en) * | 2008-01-07 | 2010-10-13 | Janssen Pharmaceutica, N.V. | Preparation of sulfamide derivatives |
US20090247618A1 (en) * | 2008-03-26 | 2009-10-01 | Ballentine Scott A | Process for preparation of benzo-fused heteroaryl derivatives |
US20090247617A1 (en) * | 2008-03-26 | 2009-10-01 | Abdel-Magid Ahmed F | Process for the preparation of benzo-fused heteroaryl sulfamates |
PE20110060A1 (en) * | 2008-06-23 | 2011-01-31 | Janssen Pharmaceutica Nv | CRYSTALLINE FORM OF (2S) - (-) - N- (6-CHLORO-2,3-DIHYDRO-BENZO [1,4] DIOXIN-2-ILMETHYL) -SULFAMIDE |
US8815939B2 (en) * | 2008-07-22 | 2014-08-26 | Janssen Pharmaceutica Nv | Substituted sulfamide derivatives |
KR20140082736A (en) * | 2011-09-29 | 2014-07-02 | 얀센 파마슈티카 엔.브이. | Process for the preparation of sulfamide derivatives |
AU2012314317A1 (en) * | 2011-09-29 | 2014-04-03 | Janssen Pharmaceutica Nv | Improved process for the preparation of sulfamide derivatives |
-
2006
- 2006-12-18 US US11/612,249 patent/US20070155827A1/en not_active Abandoned
- 2006-12-19 MY MYPI20082181A patent/MY148459A/en unknown
- 2006-12-19 KR KR1020087017574A patent/KR101415532B1/en not_active IP Right Cessation
- 2006-12-19 DK DK06847799.1T patent/DK1973539T3/en active
- 2006-12-19 BR BRPI0620014-1A patent/BRPI0620014A2/en not_active IP Right Cessation
- 2006-12-19 EP EP06847799A patent/EP1973539B1/en active Active
- 2006-12-19 ES ES06847799T patent/ES2342846T3/en active Active
- 2006-12-19 CN CN2006800524068A patent/CN101336106B/en not_active Expired - Fee Related
- 2006-12-19 DE DE602006013883T patent/DE602006013883D1/en active Active
- 2006-12-19 AT AT06847799T patent/ATE464895T1/en active
- 2006-12-19 PL PL06847799T patent/PL1973539T3/en unknown
- 2006-12-19 EA EA200870090A patent/EA015392B1/en not_active IP Right Cessation
- 2006-12-19 WO PCT/US2006/048538 patent/WO2007075751A1/en active Application Filing
- 2006-12-19 PT PT06847799T patent/PT1973539E/en unknown
- 2006-12-19 CA CA2634112A patent/CA2634112C/en not_active Expired - Fee Related
- 2006-12-19 NZ NZ569045A patent/NZ569045A/en not_active IP Right Cessation
- 2006-12-19 JP JP2008547471A patent/JP5190376B2/en not_active Expired - Fee Related
- 2006-12-19 AU AU2006331733A patent/AU2006331733B2/en not_active Ceased
- 2006-12-19 SI SI200630723T patent/SI1973539T1/en unknown
-
2008
- 2008-04-04 SV SV2008002861A patent/SV2009002861A/en unknown
- 2008-06-12 IL IL192103A patent/IL192103A/en not_active IP Right Cessation
- 2008-06-19 NI NI200800176A patent/NI200800176A/en unknown
- 2008-07-04 NO NO20083036A patent/NO20083036L/en not_active Application Discontinuation
- 2008-07-21 CR CR10165A patent/CR10165A/en not_active Application Discontinuation
-
2009
- 2009-03-24 HK HK09102822.1A patent/HK1125040A1/en not_active IP Right Cessation
-
2010
- 2010-07-09 CY CY20101100647T patent/CY1110669T1/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002009694A1 (en) * | 2000-08-02 | 2002-02-07 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful for the treatment of depression |
WO2006007435A1 (en) * | 2004-06-16 | 2006-01-19 | Janssen Pharmaceutica, N.V. | Sulfamate and sulfamide derivatives for the treatment of epilepsy and related disorders |
Non-Patent Citations (1)
Title |
---|
MARYANOFF B E ET AL: "Comparison of Sulfamate and Sulfamide Groups for the Inhibition of Carbonic Anhydrase-II by Using Topiramate as a Structural Platform", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 48, no. 6, 13 December 2004 (2004-12-13), pages 1941 - 1947, XP002345002, ISSN: 0022-2623 * |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8084490B2 (en) | 2004-06-16 | 2011-12-27 | Janssen Pharmaceutica N.V. | Sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders |
US8283478B2 (en) | 2005-05-20 | 2012-10-09 | Janssen Pharmaceutica Nv | Process for preparation of sulfamide derivatives |
US8497298B2 (en) | 2005-12-19 | 2013-07-30 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels |
US8937096B2 (en) | 2005-12-19 | 2015-01-20 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder |
US8691867B2 (en) | 2005-12-19 | 2014-04-08 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction |
US8853263B2 (en) | 2006-05-19 | 2014-10-07 | Janssen Pharmaceutica Nv | Co-therapy for the treatment of epilepsy and related disorders |
KR101511574B1 (en) | 2008-03-26 | 2015-04-15 | 얀센 파마슈티카 엔.브이. | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of anxiety |
WO2009120189A1 (en) * | 2008-03-26 | 2009-10-01 | Janssen Pharmaceutica N.V. | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of anxiety |
EA019544B1 (en) * | 2008-03-26 | 2014-04-30 | Янссен Фармацевтика Н.В. | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of anxiety |
AU2008353489B2 (en) * | 2008-03-26 | 2014-11-27 | Janssen Pharmaceutica N.V. | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of anxiety |
AU2009271362B2 (en) * | 2008-06-23 | 2014-03-13 | Janssen Pharmaceutica Nv | Crystalline form of (2s)-(-)-N-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide |
US8809385B2 (en) | 2008-06-23 | 2014-08-19 | Janssen Pharmaceutica Nv | Crystalline form of (2S)-(-)-N-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide |
EA018567B1 (en) * | 2008-06-23 | 2013-08-30 | Янссен Фармацевтика Нв | Crystalline form of (2s)-(-)-n-(6-chloro-2,3-dihydrobenzo[1,4]dioxin-2-ylmethyl)sulfamide |
WO2010008776A3 (en) * | 2008-06-23 | 2011-04-07 | Janssen Pharmaceutica Nv | Crystalline form of (2s)-(-)-n-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide |
US8815939B2 (en) | 2008-07-22 | 2014-08-26 | Janssen Pharmaceutica Nv | Substituted sulfamide derivatives |
Also Published As
Publication number | Publication date |
---|---|
EA015392B1 (en) | 2011-08-30 |
CA2634112A1 (en) | 2007-07-05 |
SV2009002861A (en) | 2009-02-23 |
EP1973539B1 (en) | 2010-04-21 |
EP1973539A1 (en) | 2008-10-01 |
DK1973539T3 (en) | 2010-08-02 |
NZ569045A (en) | 2011-05-27 |
CR10165A (en) | 2009-01-14 |
CY1110669T1 (en) | 2015-06-10 |
IL192103A (en) | 2012-10-31 |
PL1973539T3 (en) | 2010-09-30 |
US20070155827A1 (en) | 2007-07-05 |
AU2006331733B2 (en) | 2013-01-10 |
KR101415532B1 (en) | 2014-07-04 |
CN101336106B (en) | 2012-09-05 |
NI200800176A (en) | 2012-05-28 |
BRPI0620014A2 (en) | 2011-10-25 |
HK1125040A1 (en) | 2009-07-31 |
JP2009520034A (en) | 2009-05-21 |
PT1973539E (en) | 2010-05-25 |
MY148459A (en) | 2013-04-30 |
JP5190376B2 (en) | 2013-04-24 |
NO20083036L (en) | 2008-09-05 |
IL192103A0 (en) | 2009-08-03 |
EA200870090A1 (en) | 2008-12-30 |
CA2634112C (en) | 2014-08-05 |
KR20080089414A (en) | 2008-10-06 |
DE602006013883D1 (en) | 2010-06-02 |
ES2342846T3 (en) | 2010-07-15 |
ATE464895T1 (en) | 2010-05-15 |
AU2006331733A1 (en) | 2007-07-05 |
CN101336106A (en) | 2008-12-31 |
SI1973539T1 (en) | 2010-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1973539B1 (en) | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression | |
CA2634255C (en) | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of mania and bipolar disorder | |
EP2150249B1 (en) | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of migraine | |
EP1968572B1 (en) | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction | |
US20080027131A1 (en) | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity | |
EP2276481B1 (en) | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of anxiety | |
ES2360135T3 (en) | USE OF BENZO-CONDENSED HETEROCICLIC SULFAMIDS DERIVATIVES FOR THE TREATMENT OF MANIA AND BIPOLAR DISORDER. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 569045 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12008501456 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008061016 Country of ref document: EG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006331733 Country of ref document: AU Ref document number: 2634112 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2008/008097 Country of ref document: MX Ref document number: 2008547471 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08064989 Country of ref document: CO |
|
ENP | Entry into the national phase |
Ref document number: 2006331733 Country of ref document: AU Date of ref document: 20061219 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200870090 Country of ref document: EA Ref document number: 1020087017574 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2957/KOLNP/2008 Country of ref document: IN Ref document number: CR2008-010165 Country of ref document: CR Ref document number: 2006847799 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200680052406.8 Country of ref document: CN |
|
ENP | Entry into the national phase |
Ref document number: PI0620014 Country of ref document: BR Kind code of ref document: A2 Effective date: 20080619 |